MedTrace Logo

Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study

NCT01522742 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2017-03-17

No results posted yet for this study

Summary

The main aims of this study are to determine whether: a) psoriasis patients with or without arthritis have more cardiovascular inflammation than healthy subjects and b)3 months of etanercept (enbrel) therapy (prescribed to psoriasis patients with or without arthritis by their treating clinicians) will decrease cardiovascular inflammation.

Conditions

Sponsors & Collaborators

  • Immunex Corporation

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Steven K Grinspoon, MD · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01522742 on ClinicalTrials.gov